Breakthrough in Go Global strategy: Uni-Bio Science (00512.HK) obtained U.S. clinical approval for its self-developed innovative FAP target core drug, unlocking over one trillion market space.

According to the latest information from the Wisdom Financial APP, a significant milestone has been reached in the field of medical innovation in China. Farlong Pharmaceutical (00512.HK) has officially received FDA approval in the United States to conduct Phase I/II clinical trials for its globally innovative radiopharmaceutical drug GPN01530, which is developed independently, for diagnosing solid tumors.